MBIO earnings analysis
What we found in MBIO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Mustang Bio reported a challenging fourth quarter, with no revenue earned and a net loss of $955,000. Operating expenses have increased compared to the prior period, primarily due to a rise in research and development costs. The company continues to face regulatory hurdles and must regain compliance with Nasdaq listing rules.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Increased R&D Expenses
- R&D expenses rose approximately $1.1 million from $(1.0) million to $0.2 million year-over-year.
- Continuing Net Losses
- Net loss increased significantly from $(153,000) in Q1 2025 to $(955,000) in Q1 2026.
- Regulatory Compliance Deadline
- Mustang has a 180-day grace period until October 12, 2026, to regain compliance with Nasdaq's bid price requirement.
- Material Weakness Identified
- Accumulated deficit reached $399.6 million as of March 31, 2026, indicating ongoing financial difficulties.
- Cash Position
- Cash and cash equivalents decreased to $16.3 million compared to higher balances seen in previous quarters.
- Operating Cash Flow Improvement
- Net cash used in operating activities decreased from $(1.4 million) in Q1 2025 to $(1.0 million) in Q1 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Risk of Delisting
- The company is at risk of being delisted from Nasdaq if it fails to comply with the $1.00 closing bid price requirement.
- Regulatory Approval Uncertainty
- There is no guarantee that any of Mustang's product candidates will receive regulatory approval.
- Ongoing Financial Losses
- Continued operating losses are anticipated, raising concerns about the company's long-term viability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.07
What they said about what is next.
Management anticipates continued operating losses and negative cash flows for the foreseeable future.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MBIO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever